<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Palifermin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Palifermin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Palifermin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11405" href="/d/html/11405.html" rel="external">see "Palifermin: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="130437" href="/d/html/130437.html" rel="external">see "Palifermin: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F205729"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Kepivance</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F205743"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Chemoprotective Agent;</li>
<li>
                        Keratinocyte Growth Factor</li></ul></div>
<div class="block doa drugH1Div" id="F205731"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9e8fd4a1-4c37-4837-8ba7-bae48d43b75b">Oral mucositis associated with autologous hematopoietic stem cell transplant conditioning regimens</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;display:inline">
<b>Oral mucositis associated with autologous hematopoietic stem cell transplant (HSCT) conditioning regimens:</b>
<b>IV:</b> 60 mcg/kg/day for 3 consecutive days before and 3 consecutive days after myelotoxic therapy; total of 6 doses (Spielberger 2004).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Administer first 3 doses prior to myelotoxic therapy, with the third dose given 24 to 48 hours before beginning the myelotoxic conditioning regimen. Administer the last 3 doses after completion of the myelotoxic conditioning regimen, with the first of these doses beginning after (but on the same day) as HSCT infusion and at least 7 days after the most recent palifermin dose.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50989989"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, based on a pharmacokinetic study, renal impairment has minimal to no impact on palifermin pharmacokinetics.</p></div>
<div class="block doha drugH1Div" id="F50987346"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F3062245"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F55211834"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="130437" href="/d/html/130437.html" rel="external">see "Palifermin: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b22cb377-fb1a-465a-b40f-7c38d5d701e4">Oral mucositis associated with autologous hematopoietic stem cell transplant conditioning regimens; prevention or treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral mucositis associated with autologous hematopoietic stem cell transplant (HSCT) conditioning regimens; prevention or treatment (decrease severity of): N</b>
<b>ote:</b> Although an FDA-approved indication, administration of palifermin is not recommended due to adverse effect profile, potential negative effects on cancer outcomes, cost, and restricted availability (Patel 2021).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: IV: 60 mcg/kg/day once daily for 3 consecutive days before myelotoxic therapy, with the third dose administered 24 to 48 hours before conditioning regimen and for 3 consecutive days after myelotoxic conditioning therapy. The first of the postconditioning doses is given on the same day as HSCT infusion (after infusion is complete) and at least 7 days after the most recent dose of palifermin. Total regimen is 6 doses.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cc8ed06b-11c6-4b93-a3e8-92af6ca08ea1">Oral mucositis associated with allogeneic hematopoietic stem cell transplant conditioning regimens; prevention or treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral mucositis associated with allogeneic hematopoietic stem cell transplant (HSCT) conditioning regimens; prevention or treatment (decrease</b>
<b> severity of):</b> Limited data available: <b>Note:</b> Routine administration of palifermin is not recommended due to adverse effect profile, potential negative effects on cancer outcomes, cost, and restricted availability.</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: IV: 60 mcg/kg/day once daily for 3 consecutive days before myelotoxic therapy, with the third dose administered 24 to 48 hours before conditioning regimen begins and for 3 consecutive days after myeloablative conditioning therapy. The first of the postconditioning doses is given on the same day as HSCT infusion (after infusion is complete) and at least 7 days after the most recent dose of palifermin. Total regimen is 6 doses (Lauritano 2014; Morris 2016; POGO [Sung 2017]).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F55211835"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, based on a pharmacokinetic study, renal impairment has minimal to no impact on palifermin pharmacokinetics.</p></div>
<div class="block dohp drugH1Div" id="F55211836"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F205709"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Incidences are reported as part of combination chemotherapy regimens in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (28%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema of skin (32%), pruritus (35%), skin rash (62%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia (16%), increased serum amylase (62%), increased serum lipase (28%), mouth discoloration (≤17%), tongue discoloration (≤17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Mouth edema (≤17%), tongue edema (≤17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (47% to 50%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dysesthesia (12%; including hyperesthesia, hypoesthesia, paresthesia), pain (16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (39%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (2%; no evidence of neutralizing activity)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (10%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Palmar-plantar erythrodysesthesia (Keijzer 2007), papular rash (King 2009)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Genital edema (vaginal), vaginal disease (erythema)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Cataract</p></div>
<div class="block coi drugH1Div" id="F205721"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F205707"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Mucocutaneous effects: Edema, erythema, pruritus, rash, oral/perioral dysesthesia, taste alteration, tongue discoloration, and tongue thickening may occur; instruct patients to report mucocutaneous effects. The median onset of cutaneous toxicities (following initial dose) is 6 days; median duration is 5 days.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Nonhematologic malignancies: Safety and efficacy have not been established with nonhematologic malignancies; effect on the growth of keratinocyte growth factor (KGF) receptor expressing, nonhematopoietic human tumors is not known. Palifermin has been shown to enhance the growth of epithelial tumor cell lines <i>in vitro</i>.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Myelotoxic chemotherapy: Do not administer within 24 hours before, during, or after myelotoxic chemotherapy; may increase the severity and duration of oral mucositis (due to the increased sensitivity of rapidly dividing epithelial cells).</p></div>
<div class="block foc drugH1Div" id="F205716"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Kepivance: 5.16 mg (1 ea); 6.25 mg (1 ea [DSC])</p></div>
<div class="block geq drugH1Div" id="F205705"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16323592"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Kepivance Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5.16 mg (per each): $3,976.33</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F205718"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Administer by IV bolus. If heparin is used to maintain the patency of the IV line, flush line with saline prior to and after palifermin administration. Do not administer palifermin during or within 24 hours before or after chemotherapy. Allow solution to reach room temperature prior to administration; do not use if at room temperature &gt;1 hour. Do not filter.</p></div>
<div class="block admp drugH1Div" id="F55211838"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IV: Administer by IV bolus. Allow solution to reach room temperature while protecting from light prior to administration; do not use if at room temperature &gt;1 hour. If heparin is used to maintain the patency of the IV line, flush line with normal saline prior to and after palifermin administration. Do not administer palifermin during or within 24 hours before or after chemotherapy. Do not filter.</p></div>
<div class="block hazard drugH1Div" id="F49132759"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 2]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block use drugH1Div" id="F205717"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral mucositis:</b> To decrease the incidence and duration of severe oral mucositis associated with hematologic malignancies in patients receiving myelotoxic therapy in the setting of autologous hematopoietic stem cell support (when the preparative regimen is expected to result in mucositis ≥ grade 3 in the majority of patients).</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: Safety and efficacy have not been established for nonhematologic malignancies. Palifermin is not recommended with conditioning regimens containing melphalan 200 mg/m<sup>2</sup>. Palifermin was not effective in decreasing the incidence of severe mucositis in patients with hematologic malignancies receiving myelotoxic therapy in the setting of allogeneic hematopoietic stem cell support.</p></div>
<div class="block cyt drugH1Div" id="F13299811"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F205711"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Antineoplastic Agents: Palifermin may enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased.  Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparin: May increase the serum concentration of Palifermin. Management: If heparin is used to maintain an intravenous line, rinse the line with saline prior to and after palifermin administration.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparins (Low Molecular Weight): May increase the serum concentration of Palifermin.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F205723"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Based on data from animal reproduction studies, in utero exposure to palifermin may cause fetal harm.</p></div>
<div class="block brc drugH1Div" id="F14186878"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if palifermin is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Because of the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during therapy and for at least 2 weeks after the last palifermin dose.</p></div>
<div class="block mop drugH1Div" id="F14186938"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for oral mucositis.</p></div>
<div class="block pha drugH1Div" id="F205706"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Palifermin is a recombinant keratinocyte growth factor (KGF) produced in <i>E. coli</i>. Endogenous KGF is produced by mesenchymal cells in response to epithelial tissue injury. KGF binds to the KGF receptor resulting in proliferation, differentiation and migration of epithelial cells in multiple tissues, including (but not limited to) the tongue, buccal mucosa, esophagus, and salivary gland.</p></div>
<div class="block phk drugH1Div" id="F205720"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Half-life elimination: Children and Adolescents: Mean range: 2.6 to 5.6 hours; Adults: 4.5 hours (range: 3.3 to 5.7 hours).</p></div>
<div class="block phksp drugH1Div" id="F51192040"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Older adult: In a single-dose study of 90 mcg/kg/dose or 180 mcg/kg/dose, average clearance was ~30% lower in patients &gt;65 years of age compared with patients ≤65 years of age.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5539910"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Kepivance</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Kepivance</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Kepivance</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Kepivance</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Kepivance</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Kepivance</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Kepivance</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Kepivance</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Kepivance</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Kepivance</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Kepivance</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Kepivance</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Kepivance</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Kepivance</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Kepivance | Palifermin Amgen</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Kepivance</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Kepivance</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Kepivance</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Kepivance</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17341273">
<a name="17341273"></a>Keijzer A, Huijgens PC, van de Loosdrecht AA. Palifermin and palmar-plantar erythrodysesthesia. <i>Br J Haematol</i>. 2007;136(6):856-857. doi:10.1111/j.1365-2141.2007.06509.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/palifermin-drug-information/abstract-text/17341273/pubmed" id="17341273" target="_blank">17341273</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Kepivance (palifermin) [prescribing information]. Stockholm, Sweden: Swedish Orphan Biovitrum AB; July 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19221263">
<a name="19221263"></a>King B, Knopp E, Galan A, Nuovo G, Tigelaar R, McNiff J. Palifermin-associated papular eruption. <i>Arch Dermatol</i>. 2009;145(2):179-182. doi:10.1001/archdermatol.2008.548<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/palifermin-drug-information/abstract-text/19221263/pubmed" id="19221263" target="_blank">19221263</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Lauritano D, Petruzzi M, Di Stasio D, Lucchese A. Clinical effectiveness of palifermin in prevention and treatment of oral mucositis in children with acute lymphoblastic leukaemia: a case-control study. <i>Int J Oral Sci</i>. 2014;6(1):27-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/palifermin-drug-information/abstract-text/24357856/pubmed" id="24357856" target="_blank">24357856</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Morris J, Rudebeck M, Neudorf S, et al. Safety, pharmacokinetics, and efficacy of palifermin in children and adolescents with acute leukemias undergoing myeloablative therapy and allogeneic hematopoietic stem cell transplantation: a Pediatric Blood and Marrow Transplant Consortium Trial. <i>Biol Blood Marrow Transplant</i>. 2016;22(7):1247-1256.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/palifermin-drug-information/abstract-text/26968792/pubmed" id="26968792" target="_blank">26968792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34252760">
<a name="34252760"></a>Patel P, Robinson PD, Baggott C, et al. Clinical practice guideline for the prevention of oral and oropharyngeal mucositis in pediatric cancer and hematopoietic stem cell transplant patients: 2021 update. <i>Eur J Cancer</i>. 2021;154:92-101. doi:10.1016/j.ejca.2021.05.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/palifermin-drug-information/abstract-text/34252760/pubmed" id="34252760" target="_blank">34252760</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15602019">
<a name="15602019"></a>Spielberger R, Stiff P, Bensinger W, et al, “Palifermin for Oral Mucositis After Intensive Therapy for Hematologic Cancers,” <i>N Engl J Med</i>, 2004, 351(25):2590-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/palifermin-drug-information/abstract-text/15602019/pubmed" id="15602019" target="_blank">15602019</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16391299">
<a name="16391299"></a>Stiff PJ, Emmanouilides C, Bensinger WI, et al, "Palifermin Reduces Patient-Reported Mouth and Throat Soreness and Improves Patient Functioning in the Hematopoietic Stem-Cell Transplantation Setting," <i>J Clin Oncol</i>, 2006, 24(33):5186-93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/palifermin-drug-information/abstract-text/16391299/pubmed" id="16391299" target="_blank">16391299</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25818385">
<a name="25818385"></a>Sung L, Robinson P, Treister N, et al. Guideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation. <i>BMJ Support Palliat Care</i>. 2017;7(1):7-16. doi:10.1136/bmjspcare-2014-000804<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/palifermin-drug-information/abstract-text/25818385/pubmed" id="25818385" target="_blank">25818385</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li></ol></div><div id="topicVersionRevision">Topic 10161 Version 161.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
